A chronological record of peer-reviewed Epithalon research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Epithalonworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Telomerase Activation. Primary indications investigated: Telomerase activation, Anti-aging, Cellular longevity.
Behavioral testing study examining epithalon effects on learning, memory retention, and age-related cognitive decline in multiple maze tasks.
Study in rat optic nerve injury model examining epithalon effects on retinal ganglion cell survival, BDNF expression, and axon regeneration.
In-vitro study using human peripheral blood lymphocytes examining epithalon-induced telomerase reactivation and telomere lengthening.
In-vitro study examining epithalon effects on replicative senescence, senescence markers (p16, p21), and cellular lifespan extension.
Study of epithalon effects on brain-derived neurotrophic factor expression and hippocampal neurogenesis in aged mice.
Study measuring epithalon effects on thymic cellularity, T-cell subset distribution, and T-cell receptor excision circles (TRECs).
Study examining epithalon effects on skin collagen content, dermal thickness, and mechanical properties of aged skin.
Study measuring epithalon effects on oxidative stress markers, antioxidant enzyme activities, and lipid peroxidation in aged tissues.
Study of epithalon effects on brain mitochondrial respiratory chain function, ATP synthesis capacity, and oxidative phosphorylation.
Study examining epithalon effects on pineal gland histology, melatonin synthesis capacity, and circadian melatonin rhythm restoration.
In-vitro study showing epithalon activated telomerase in human somatic cells and promoted telomere elongation.
Study in aged mice demonstrating epithalon restores telomerase activity in immune organs and improves T-cell mediated immunity.
Sleep polysomnography study in aged rats examining epithalon effects on sleep architecture, REM sleep, and circadian consolidation.
Study of epithalon effects on carcinogen (DMBA)-induced tumorigenesis and lifespan in aging mice with documentation of tumor incidence.
Study comparing epithalon alone, caloric restriction alone, and combination treatment on lifespan and aging biomarkers.
Study examining epithalon effects on circulating testosterone levels, Leydig cell function, and sexual behavior in aged male rats.
Study in telomerase-knockout mice examining epithalon effects on telomerase reactivation, telomere length, and lifespan extension.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Epithalon is L2 (Preclinical Evidence): consistent animal study results but no human data. Treat each study as one data point, not a conclusion.
PeptideMark indexes 33 studies on Epithalon: 3 human studies, 18 animal studies, 8 in-vitro, and 4 reviews. The current evidence level is L2 — preclinical evidence.
The earliest indexed peer-reviewed study on Epithalon in the PeptideMark library was published in 1999 (Mechanisms of Ageing and Development). Research activity has continued through 2009.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Epithalon has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.